Elosulfase alfa (Vimizim)
The objective of this review was to evaluate the beneficial and harmful effects of elosulfase alfa (ESA) 2mg/kg IV once weekly as long-term enzyme replacement therapy in patients with mucopolysaccharidosis IVA; Morquio A syndrome (MPS IVA)
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review was to evaluate the beneficial and harmful effects of elosulfase alfa (ESA) 2mg/kg IV once weekly as long-term enzyme replacement therapy in patients with mucopolysaccharidosis IVA; Morquio A syndrome (MPS IVA) |
---|---|
Physical Description: | 1 PDF file illustration |